AstraZeneca PLC

NYSE:AZN

Drug Manufacturers - General

Healthcare
$178.76 -1.71%

-$3.04 today

Market cap
$277.23B
Beta
0.21
P/E (TTM)
25.7
EPS (TTM)
$6.75
Dividend yield
1.80%
52W Low $137.22High $212.71

Volume 2.54M

Average 1.96M

AZN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

AstraZeneca PLCNYSE: AZN

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA grows, but more slowly than its trailing trend

Q3 FY2026 EBITDA of $5.9B rose 13.0% year over year, behind the +18.6% change in trailing-twelve-month EBITDA. Sequentially, it rose 14.4% from the prior quarter. Over 3 fiscal years it compounded at +29.7% a year.

Context

  • EBITDA amounted to 33.8% of revenue in FY2025, up 5.2 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 18 analysts of $29.94B (+51.0%) for the fiscal year ending Dec 2026, a step up from the +28.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$5.9B+14.4% QoQ
Last fiscal yearDec 2025
$19.83B+28.4% YoY
LTMSep 2026
$21.37B+18.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.0%+54.7%+41.7 pp
1 year+28.4%+51.0%+22.6 pp
3-year CAGR+29.7%+21.2%-8.5 pp
5-year CAGR+16.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
19.83B USD
Year-over-year change
+28.4%
4-year CAGR
+40.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How AZN compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +18.6% is the 3rd highest of 10, against a peer median of +4.7%.
  • EBITDA amounts to 34.4% of revenue for AZN, versus a peer median of 36.6%.
AZN Competitors
EBITDA for AZN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 180.91B DKK+4.7%+26.8%54.9%
LLYEli Lilly and CompanyLTM Jun 2026$43.3B USD+103.7%+54.1%54.4%
JNJJohnson & JohnsonLTM Sep 2026$30.81B USD-22.1%+15.6%31.0%
ABBVAbbVie Inc.LTM Sep 2026$24.15B USD+88.7%-10.0%36.6%
NVSNovartis AGLTM Jun 2026$22.26B USD-2.0%+16.1%40.0%
AZNAstraZeneca PLCLTM Sep 2026$21.37B USD+18.6%+29.7%34.4%
AMGNAmgen Inc.LTM Jun 2026$17.62B USD+10.8%+11.6%46.2%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$16.82B USD+11.6%-7.5%34.2%
MRKMerck & Co., Inc.LTM Jun 2026$13.93B USD-44.4%+9.9%21.0%
PFEPfizer Inc.LTM Jun 2026$13.49B USD-33.1%-25.8%21.2%
Peer median (excluding AZN) —+4.7%+11.6%36.6%

Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.42B44.35B45.81B54.07B58.74B
Cost of Revenue12.44B12.39B8.27B10.21B10.63B
Gross Profit24.98B31.96B37.54B43.87B48.11B
Gross Margin66.8%72.1%82.0%81.1%81.9%
Research & Development9.74B9.76B10.94B13.58B14.23B
Selling, General & Admin15.59B17.98B18.22B20.22B20.51B
Operating Expenses23.92B28.2B29.35B33.86B34.36B
Depreciation & Amortization4.1B5.25B4.93B5.07B5.73B
EBITDA5.11B9.09B13.42B15.44B19.83B
EBITDA Margin13.7%20.5%29.3%28.6%33.8%
Operating Income1.06B3.76B8.19B10B13.74B
Operating Margin2.8%8.5%17.9%18.5%23.4%
Interest Income43M81M301M345M360M
Interest Expense1.28B1.33B1.59B1.68B1.69B
Other Income / Expenses(1.32B)(1.26B)(1.29B)(1.31B)(1.34B)
Income Before Tax(265M)2.5B6.9B8.69B12.4B
Pre-Tax Margin-0.7%5.6%15.1%16.1%21.1%
Income Tax Expense(380M)(792M)938M1.65B2.17B
Net Income112M3.29B5.96B7.04B10.26B
Net Margin0.3%7.4%13.0%13.0%17.5%
EPS (Basic)0.082.123.814.546.60
EPS (Diluted)0.082.113.814.506.54
Weighted Avg Shares1.42B1.55B1.56B1.55B1.55B
Weighted Avg Shares (Diluted)1.43B1.56B1.56B1.56B1.56B

AstraZeneca PLC

NYSE:AZN

Intrinsic Alpha fair value

Locked

Current Price

$178.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.